Published online Mar 28, 2021. doi: 10.3748/wjg.v27.i12.1240
Peer-review started: December 19, 2020
First decision: January 10, 2021
Revised: January 17, 2021
Accepted: March 12, 2021
Article in press: March 12, 2021
Published online: March 28, 2021
Processing time: 95 Days and 15.1 Hours
Hepatitis E virus (HEV) infection among patients with pre-existing chronic liver disease and organ-transplant recipients on immunosuppressive therapy can result in decompensated liver disease and death.
The prevalence of HEV infection in solid organ transplant (SOT) recipients varies from one organ to another. The disease burden and clinical outcomes of HEV infection in such patients are under-investigated.
To demonstrate the prevalence of HEV infection in SOT recipients.
Eligible articles were searched through Ovid MEDLINE, EMBASE, and the Cochrane Library. The inclusion criteria are adult patients with history of SOT. HEV infection is confirmed by either HEV-immunoglobulin G, HEV-immunoglobulin M, or HEV RNA assay.
Of 563 citations, a total of 22 studies (n = 4557) were included in the meta-analysis. The pooled estimated prevalence of HEV infection in SOT patients was 20.2% (95%CI: 14.9-26.8). The pooled estimated prevalence of HEV infection in each organ transplant was as followed: liver (27.2%; 95%CI: 20.0-35.8), kidney (12.8%; 95%CI: 9.3-17.3), heart (12.8%; 95%CI: 9.3-17.3), and lung (5.6%; 95%CI: 1.6-17.9). The comparison across all organ transplant was statistically significant (Q = 16.721, P = 0.002). The subgroup analyses showed that the prevalence of HEV infection among SOT recipients was significantly higher in middle-income countries compared to high-income countries. The pooled estimated prevalence of de novo HEV infection was 5.1% (95%CI: 2.6-9.6) and the pooled estimated prevalence of acute HEV infection was 4.3% (95%CI: 1.9-9.4).
HEV infection is common in SOT recipients, especially in middle-income countries. The prevalence of HEV infection in lung transplant recipients is considerably less common than other organ transplants.
The results of this study offer a preliminary perspective on the magnitude of disease burden from HEV infection, especially in middle-income countries. In the future, large-scale observational studies investigating these associations between HEV infection, patient outcomes, and allograft outcomes are needed to help guide the management of HEV infection in SOT recipients. We also highlight the need for studies from low-income and middle-income countries, as the prevalence of HEV infection from these countries is under-reported.